Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

NCT06660862 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Darolutamide
DRUG: Physician choice Androgen Deprivation (Hormone) Therapy

Sponsor

University of Chicago